Volume 13, Number 8—August 2007
Osteomyelitis of Parietal Bone in Melioidosis
To the Editor: In Europe and the United States, melioidosis is a rare disease, with no cases reported thus far from Slovenia. However, it is a relatively common disease in certain areas of Southeast Asia and northern Australia. Potentially fatal, this disease is caused by the gram-negative bacillus Burkholderia pseudomallei, an environmental organism found in the soil and water of disease-endemic areas. Human infections are mostly acquired through percutaneous inoculation during contact with contaminated water and soil, although inhalation is also a recognized route of acquisition (1). Heavy monsoon rain is associated with severe disease course (2). Melioidosis was reported in some persons injured in the Tsunami in 2004 (3). The disease has a wide spectrum of signs and symptoms (4). Osteomyelitis is a rare manifestation. It occurs in <5% of cases and is a clinical challenge to diagnose and treat (1,4,5).
We describe a case of melioidosis in a previously healthy, 40-year-old Slovenian man. The patient had been working as a basketball trainer in Jordan for the previous 12 months and was traveling to Brunei in mid-summer 2006, 14 days before the illness started. While visiting Brunei, he sustained a minor head trauma when he hit his head on a night table at the hotel. Ten days later, high-grade fever up to 40°C developed, without any other signs or symptoms of disease. After returning to Jordan, the patient was admitted to a local hospital and received different antimicrobial agents without any improvement of his medical condition. After 6 weeks of unsuccessful treatment, he decided to continue medical treatment in Slovenia.
On admission to our hospital, he reported headache and persistent high fever of 6 weeks’ duration. Physical examination indicated high fever (39.5°C) and occipital swelling without any neurologic deficits or other abnormal findings. Initial complete blood cell count, liver function test results, blood urea nitrogen levels, and creatinin levels were normal. C-reactive protein was 60 mg/L, and erythrocyte sedimentation rate was 47 mm/h. Results of chest radiograph and abdominal ultrasound were normal. Results of repeated blood cultures and urinalysis were negative.
The suspected clinical diagnosis was brucellosis (the patient had eaten unpasteurized soft cheese during his stay in Jordan, and brucellosis is endemic in the Middle East). While waiting for Brucella spp. tests, we began empirical antimicrobial drug treatment with doxycycline. The patient’s condition improved promptly. He became afebrile after 4 days of therapy. In the following week, ultrasound of occipital area soft tissue was performed, and posttraumatic seroma was diagnosed. B. pseudomallei was isolated from the seroma on sheep blood agar and identified with VITEK 2 gram-negative identification card (bioMérieux, Marcy l’Etoile, France). The isolate was sensitive to piperacillin, piperacillin-tazobactam, ceftazidime, imipenem, meropenem, and chloramphenicol. It was resistant to aminoglicosides (gentamicin, tobramycin, amikacin, netilmicin), colistin, and polymyxin B. Etest MIC showed susceptibility to doxycycline (MIC 2 μg/mL) and trimethoprim/sulfamethoxazole (TMP/SMX) (MIC 1/19 μg/mL). Susceptibility of B. pseudomallei to TMP/SMX was tested with Etest because the disc-diffusion method is inappropriate and can overestimate the extent of resistance (6).
The patient later recalled going on a jungle trip in Brunei the day after his accident. During the trip, he scratched his head, and the skin started to bleed. Thus, he likely inoculated bacteria into the subcutaneous tissue of the head. Fever developed 10 days later.
Computed tomography of the scalp was performed (Figure), and osteomyelitis of the right parietal bone was detected. Magnetic resonance imaging (MRI) excluded involvement of intracranial tissues. Doxycycline was stopped and, as recommended, treatment with ceftazidime and oral TMP/SMX was started. The patient received 8 weeks of intensive parenteral therapy. Once he was discharged, he received 4 months of oral eradication therapy with TMP/SMX and doxycycline. The outcome was excellent. He is now without signs and symptoms of disease, has normal laboratory test results, and has no signs of inflammation on MRI.
Involvement of the skin and soft tissue is common in melioidosis (7). Osteomyelitis is a rare manifestation, usually part of a disseminated infection involving metaphyseal regions of long bones and vertebral bodies. Localized bone involvement is very rare (8). In a Thailand group of 21 patients with musculoskeletal melioidosis, all were initially treated with surgical debridement, followed by long course of antimicrobial therapy (9). A single report of parietal bone osteomyelitis was found in the literature; it was connected to a cerebral abscess due to hematogenous dissemination (10). Because of the specific location of the osteomyelitis (close to the leptomeninges), nonextensive bone damage, and good initial response to antimicrobial therapy, we decided on conservative therapy only.
Melioidosis, although a rare disease, should be considered in the differential diagnosis of any febrile illness in patients returning from disease-endemic regions, especially Thailand and northern Australia. Without special awareness of this possibility, microbiologic laboratories in nonendemic regions could likely misidentify the bacteria and consequently misdiagnose the organism.
- Cheng AC, Currie BJ. Melioidosis: epidemiology, pathophysiology and management. Clin Microbiol Rev. 2005;18:383–416.
- Currie BJ, Jacups SP. Intensity of rainfall and severity of melioidosis, Australia. Emerg Infect Dis. 2003;9:1538–42.
- Athan E, Allworth AM, Engler C, Bastian I, Cheng CA. Melioidosis in tsunami survivors. Emerg Infect Dis. 2005;11:1638–9.
- Currie BJ. Burkholderia pseudomallei and Burkholderia mallei: melioidosis and glanders. In: Mandell GL, Bennet JE, Dolin R, editors. Principles and practice of infectious diseases. Vol. 2. Oxford (UK): Churchill Livingstone; 2005. p. 2622–32.
- Currie BJ, Fisher DA, Howard DM, Burrow JN, Lo D, Selva-Nayagam S, Endemic melioidosis in tropical northern Australia: a 10-year prospective study and review of the literature. Clin Infect Dis. 2000;31:981–6.
- Piliouras P, Ulett G, Ashhurst-amith C, Hirst RG, Norton RE. A comparison of antibiotic susceptibility testing methods for cotrimoxazole with Burkholderia pseudomallei. Int J Antimicrob Agents. 2002;19:427–9.
- Wang YS, Wong CH, Kurup A. Cutaneous melioidosis and necrotizing fasciitis caused by Burkholderia pseudomallei. Emerg Infect Dis. 2003;9:1484–5.
- Subhadrabandhu T, Prichasuk S, Sathapatayavongs B. Localized melioidotic osteomyelitis. J Bone Joint Surg Br. 1995;77:445–9.
- Kosuwon W, Saengnipanthkul S, Mahaisavariya B, Laupattarakasem W, Kaen K. Musculosceletal melioidosis. J Bone Joint Surg Am. 1993;75:1811–5.
- Chadwick DR, Ang B, Sitoh YY, Lee CC. Cerebral melioidosis in Singapore: a review of five cases. Trans R Soc Trop Med Hyg. 2002;96:72–6.
- Figure. Axial nonenhanced computed tomography showing moth-eaten appearance of right parietal bone characteristic of osteomyelitis.
Suggested citation for this article: Miksić NG, Alikadić N, Lejko TZ, Andlovic A, Knific J, Tomažič J. Osteomyelitis of parietal bone in melioidosis [letter]. Emerg Infect Dis [serial on the Internet]. 2007 Aug [date cited]. Available from http://wwwnc.cdc.gov/eid/article/13/8/07-0479
Please use the form below to submit correspondence to the authors or contact them at the following address:
Nina Miksić, General Hospital Maribor Ljubljanska 5, 2000 Maribor, Slovenia;
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: June 30, 2010
- Page last updated: June 30, 2010
- Page last reviewed: June 30, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)